7.01 USD
-0.27
3.71%
At close Jul 29, 4:00 PM EDT
Pre-market
7.08
+0.07
1.00%
1 day
-3.71%
5 days
-4.23%
1 month
11.27%
3 months
9.19%
6 months
-20.43%
Year to date
-18.20%
1 year
-57.31%
5 years
-95.18%
10 years
-97.06%
 

About: Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Employees: 1,992

0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

43% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 35

5% more funds holding

Funds holding: 229 [Q4 2024] → 241 (+12) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 67

2.83% less ownership

Funds ownership: 64.06% [Q4 2024] → 61.23% (-2.83%) [Q1 2025]

15% less call options, than puts

Call options by funds: $45.3M | Put options by funds: $53.3M

23% less capital invested

Capital invested by funds: $825M [Q4 2024] → $631M (-$194M) [Q1 2025]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$6
14%
downside
Avg. target
$7.33
5%
upside
High target
$9
28%
upside

3 analyst ratings

positive
0%
neutral
33%
negative
67%
B of A Securities
Alec Stranahan
28%upside
$9
Neutral
Maintained
22 Jul 2025
Citigroup
Geoff Meacham
14%downside
$6
Sell
Initiated
17 Jun 2025
JP Morgan
Eric Joseph
0%downside
$7
Underweight
Maintained
9 May 2025

Financial journalist opinion

Based on 8 articles about NVAX published over the past 30 days

Positive
Zacks Investment Research
1 day ago
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Negative
Zacks Investment Research
5 days ago
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Positive
Benzinga
5 days ago
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
Novavax, Inc. NVAX on Thursday revealed preclinical data from the H5N1 avian pandemic influenza vaccine candidate.
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
Neutral
PRNewsWire
6 days ago
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts  GAITHERSBURG, Md. , July 24, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM) administration in nonhuman primates.
Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
Neutral
Zacks Investment Research
2 weeks ago
Novavax (NVAX) Rises Higher Than Market: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $6.97, denoting a +1.9% move from the preceding trading day.
Novavax (NVAX) Rises Higher Than Market: Key Facts
Positive
Zacks Investment Research
2 weeks ago
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Positive
The Motley Fool
2 weeks ago
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Positive
Zacks Investment Research
4 weeks ago
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?
Negative
Zacks Investment Research
1 month ago
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Novavax (NVAX) settling at $6.36, representing a -2.15% change from its previous close.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Positive
Zacks Investment Research
1 month ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Charts implemented using Lightweight Charts™